|本期目录/Table of Contents|

[1]庄 微综述,刘挺松审校.晚期糖基化终末产物受体在心血管疾病中的研究概况[J].医学研究与战创伤救治(原医学研究生学报),2014,16(06):629-631.[doi:10.3969/j.issn.1672-271X.2014.06.021]
点击复制

晚期糖基化终末产物受体在心血管疾病中的研究概况()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第16卷
期数:
2014年06期
页码:
629-631
栏目:
综述
出版日期:
2014-11-20

文章信息/Info

Title:
-
作者:
庄 微综述; 刘挺松审校
210002 江苏南京，南京军区南京总医院心脏内科
Author(s):
-
关键词:
晚期糖基化终末产物受体; 心血管疾病; 动脉粥样硬化; 心肌缺血再灌注损伤
Keywords:
-
分类号:
R54
DOI:
10.3969/j.issn.1672-271X.2014.06.021
文献标志码:
B
摘要:
晚期糖基化终末产物受体(receptor for advanced glycation end products，RAGE)是晚期糖基化终末产物(advanced glycation end products，AGEs)的特异性受体。 RAGE与AGEs结合可启动一系列受体后信号转导途径，导致多种细胞因子与生长因子的合成与释放，引起血流动力学、血液流变学异常、细胞基质异常增生、血管内皮损伤等病理变 化，参与大血管并发症的发生、发展过程。本文就RAGE在心血管疾病中的研究进展进行综述。
Abstract:
-

参考文献/References:

[1]Santilli F,Vazzana N,Bucciarelli LG,et al.Soluble forms of RAGE in human diseases:clinical and therapeutical implications[J].Curr Med Chem,2009,16(8):940 -952.
[2]张 奎,薛耀明,高 方,等.晚期糖基化终产物与其受体相互作用对人结肠癌细胞SW-480增殖的影响[J].医学研究生学报,2010,23(9):924-927.
[3]陈婷婷,夏金荣.晚期糖基化终产物受体特异性小干扰RNA对致纤维化细胞因子生成的抑制作用[J].医学研究生学报,2013,26(5):465-468.
[4]Neeper M,Schmidt AM,Brett J,et al.Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins[J].J Biol Chem,1992,267(21):14998-5004.
[5]Tam XH,Shiu SW,Leng L,et al.Enhanced expression of receptor for advanced glycation end-products is associated with low circulating soluble isoforms of the receptor in type 2 diabetes[J].Clin Sci,2011,120(2):81-89.
[6]Falcone C,Emanuele E,D`Angelo A,et al.Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men[J].Arterioscler Thromb Vasc Biol,2005,25(5):1032-1037.
[7]Wendt T,Harja E,Bucciarelli L,et al.RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes[J].Atherosclerosis， 2006,185(1):70-76.
[8]Cipollone F,Lezzi A,Fazia M,et al.The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques:role of glycemic control[J].Circulation,2003,108(9):1070-1077.
[9]Falcone C,Geroldi D,Buzzi MP,et al.The-374T/A RAGE polymorphism protects against future cardiac events in nondiabetic patients with coronary artery disease[J].Arch Med Res,2008,39(3):320-325.
[10]Boiocchi C,Bozzini S,Buzzi MP,et al.Age of onset of myocardial infarction is promoter polymorphism of the RAGE gene implicated[J].Rejuvenation Res,2011,14(1):67-73.
[11]Yellon DM,Hausenloy DJ.Myocardial reperfusion injury[J].N Engl J Med,2007,357(11):1121-1135.
[12]Kitano K,Usui S,Ootsuji H,et al.Rho-kinase activation in leukocytes plays a pivotal role in myocardial ischemia/reperfusion injury[J].PLoS One，2014,9 (3):922-942.
[13]McNair ED,Wells CR,Mabood Qureshi A,et al.Modulation of high sensitivity C-reactive protein by soluble receptor for advanced glycation end products [J].Mol Cell Biochem,2010,341(1/2):135-138.
[14]Theroux P,Armstrong PW,Mahaffey KW,et al.Prognostic significance of blood markers of inflammation in patients with ST-segment elevation of pexelizumab,a C5 inhibitor:a sub-study of the COMMA trial[J].Eur Heart J,2005,26(9):1964-1970.
[15]Cai XY,LU L,Wang YN,et al.Association of increased S100B,S100A6 and S100P in serum levels with acute coronary syndrome also with the severity of myocardial infarction in cardiac tissue of rat models with ischemia-reperfusion injury[J].Atherosclerosis,2011,217(2):536-542.
[16]Andrassy M,Volz HC,Lgwe JC,et al.High mobility group box-1 in ischemia-reperfusion injury of the heart[J].Circulation,2008,117(25):3216-3226.
[17]Shang L,Ananthakrishnan R,Li Q,et al.RAGE modulates hypoxia/reoxygenation injury in adult murine cardiomyocytes via JNK and GSK-3β signaling pathways [J].PLoS One,2010,5(4):10092-10096.
[18]Yamagishi S,Matsui T,Nakamura K.Kinetics,role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes[J].Curr Drug Targets,2007,8(10):1138-1143.
[19]Juranek JK,Kothary P,Mehra A,et al.Increased expression of the receptor for advanced glycation end-products in human peripheral neuropathies[J].Brain Behav，2013,3(6):701-709.
[20]潘 涛，张 均，范国峰，等.低分子肝素预防脑出血后静脉血栓的安全性研究[J].东南国防医药，2012,14(6):517-519
[21]Yamamoto Y,Yamamoto H.Controlling the receptor for advanced glycation end-products to conquer diabetic vascular complications[J].J Diabetes Investig， 2012,3(2):107-114.

相似文献/References:

[1]雷军平,曹江晨综述,郑 兴审校.Mimecan/Osteoglycin与心血管疾病[J].医学研究与战创伤救治(原医学研究生学报),2012,14(01):52.
[2]李 琦,余志龙综述,郑大东审校.他汀类药物在心血管疾病中的临床应用进展[J].医学研究与战创伤救治(原医学研究生学报),2011,13(05):438.
[3]魏佳,韩娟综述,颜浩审校.晚期糖基化终末产物受体与肺部疾病研究进展[J].医学研究与战创伤救治(原医学研究生学报),2019,21(3):291.[doi:10.3969/j.issn.1672-271X.2019.03.015]
　WEI Jia,HAN Juan reviewing,YAN Hao checking.Progress of receptor for advanced glycation end products and pulmonary disease[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2019,21(06):291.[doi:10.3969/j.issn.1672-271X.2019.03.015]

备注/Memo

备注/Memo:
-
更新日期/Last Update: 2014-11-20